Protein-DNA interaction at the origin of neurological diseases: A hypothesis

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 375-391

  Jiménez, Juan S ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer's disease; amyotrophic lateral sclerosis; Parkinson's disease; polyglutamine diseases; transmissible spongiform encephalopathy

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANDROGEN RECEPTOR; ATAXIN 1; ATAXIN 3; ATAXIN 7; COPPER ZINC SUPEROXIDE DISMUTASE; POLYGLUTAMINE; PRION PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE MARKER; DNA BINDING; DNA STRUCTURE; HUMAN; HUNTINGTON CHOREA; LEWY BODY; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENICITY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DNA INTERACTION; PROTEIN FOLDING; REVIEW; SPINOCEREBELLAR DEGENERATION;

EID: 78650802687     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100189     Document Type: Review

References (226)

1. Duycakerts C, Dickson DW (2003) Neuropathology of Alzheimer's disease. In Neurodegeneration. The molecular pathology of dementia and movement disorders, Dickson DW, ed. Neuropath. Press, Basel, pp. 47-65.
2. Huang HC, Jiang ZF (2009) Accumulated amyloid-beta pep-tide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. JAlzheimers Dis 16, 15-27.
3. Small SA, Duff K (2008) Linking Abeta and tau in the late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60, 534-542.
4. Avila J, Hernandez F (2007) GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7, 1527-1533.
5. Grundke-Iqbal I, Rolkova G, Konstekova E, Iqbal K (2006) Biological markers in Alzheimer's disease. Bratisl Lek Listy 107, 359-365.
6. Mandelkow E, von Bergen M, Biernat J, Mandelkow EM (2007) Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17, 83-90.
7. Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.
8. Casley CS, Canevary L, Land JM, Clark JB, Sharpe MA (2002) (-Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. JNeurochem 80, 91-100.
9. Pollard HB, Rojas E, Arispe N (1993) A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid (protein (A P) in phospholipid bilayer membranes. Ann N YAcad Sci 695, 165-168.
10. Bhatia R, Lin H, Lal R (2000) Fresh and globular amyloid ( protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 14, 1233-1243.
11. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Kraff GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid coligomers. J. Neurosci 24, 10191-10200.
12. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ (1998) Amyloid-peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785, 195-206.
13. Kienlen-Campard P, Miolet S, Tasiaux B, Octave JN (2002) Intracellular amyloid-(1-42, but not extracellular soluble amyloid-( peptides induces neuronal apoptosis. J Biol Chem 277, 15666-15670.
14. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20, 814-822.
15. Guo JP, Arai T, Miklossy J, McGeer PL (2006) A( and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 103, 1953-1958.
16. Biickig A, Tikkanen R, Herzog V, Schmitz A (2002) Cytoso-lic and nuclear aggregation of the amyloid (-peptide following its expression in the endoplasmic reticulum. Histochem Cell Biol 118, 353-360.
17. Hegde ML, Anitha S, Latha KS, Mustak MS, Stein R, Ravid R, Rao KS (2003) First evidence for helical transitions in su-percoiled DNA by amyloid ( peptide (1-42) and aluminium JMol Neurosci 22, 19-31.
18. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira J, Tabira T (2005) Intracellular A(42 activates p53 promoter: a pathway to neurodegenera-tion in Alzheimer's disease FASEBJ19, 255-257.
19. Ahn BW, Song DU, Jung YD, Chay KO, Chung MA, Yang SY, Shin BA (2000) Detection of (-Amyloid peptide aggregation using DNA electrophoresis. Anal Biochem 284, 401405.
20. Yu H, Ren J, Qu X (2007) Time-dependent DNA condensation induced by amyloid beta-peptide. Biophys J 92, 185-191.
21. Barrantes A, Rejas MT, Benitez MJ, Jimenez JS (2007) Interaction between Alzheimer's A( 1-42 peptide and DNA detected by surface plasmon resonance. J Alzheimers Dis 12, 345-355.
22. Johnstone EM, Bebbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP (1996). Nuclear and cytoplasmic localization of the (-amyloid peptide (1-43) in transfected 293 cells. Biochem Biophys Res Commun 220, 710-718.
23. Hernandez F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64, 2219-2233
24. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72, 1858-1862.
25. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
26. Montejo de Garcini E, Serrano L, Avila J (1986) Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer Disease. Biochem Bio-phys Res Commun 141, 790-796.
27. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of T into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 98, 6923-6928.
28. von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E (2005) Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta 1739, 158-166.
29. Kuret J, Congdon EE, Li G, Yin H, Yu X, Zhong Q (2005) Evaluating triggers and enhancers of tau fibrillization. Microsc-Res Tech 67, 141-155.
30. Avila J (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBSLett 580, 2922-2927.
31. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, In-gelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
32. Lu Q, Wood JG (1993) Characterization of fluorescently derivatized bovine tau protein and its localization and functions in cultured chinese hamster ovary cells. Cell Motil Cytoskel 25, 190-200.
33. Lambert MP, Sabo S, Zhang C, Enam SA, Klein WL (1995) Constitutive Alzheimer's-type tau epitopes in a neuritigenic rat CNS cell line. Neurobiol Aging 16, 583-589.
34. Thurston VC, Pena P, Pestell R, Binder LI (1996) Nucleolar localization of the microtubule-associated protein tau in neuroblastomas using sense and anti-sense transfection strategies. CellMotil Cytoskel 38, 100-110.
35. Cross DC, Muiioz JP, Hernandez P, Maccioni RB (2000) Nuclear and cytoplasmic tau proteins llfrom human nonneuronal cells share common structural and functional features with braintau. J Cell Biochem 78, 305-317.
36. Sjoberg MK, Shestakova E, Mansuroglu Z, Maccioni RB, Bonnefoy E (2006) Tau protein binds pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J Cell Science 119, 2025-2034.
37. Corces VG, Manso R, De la Torre J, Avila J, Nasr A, Wiche G (1980) Effects of DNA on microtubule assembly. Eur J Biochem 105, 7-16.
38. Hua Q, He RQ (2003) Tau could protect DNA double helix structure. Biochim Biophys Acta 1645, 205-211.
39. Hua Q, He RQ (2002) Effect of phosphorylation and aggregation on tau binding to DNA Protein Pept Lett 9, 349-357.
40. Wei Y, Qu M, Wang X-S, Chen L, Wang D-L, Liu Y, Hua Q, He R-Q (2008) Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxida-tion. Plos ONE 3, e2600.
41. Spillantini MG, Goedert M (2000) The a-synucleinopathies: Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Ann NY Acad Sci 920, 16-27.
42. Spillantini MG, Schmidt ML, ee VM, Trojanowsky JQ, Jakes R, Goedert M (1997) a-synuclein in Lewy bodies. Nature 388, 839-840.
43. Lucking CB, Brice A (2000) a-synuclein and Parkinson's disease. Cell Mol Life Sci 57, 1894-1908.
44. Goedert M (2001) a-synuclein and neurodegenerative diseases. Nature Rev Neurosci 2, 492-501.
45. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning is natively unfolded. Biochemistry 35, 1370913715.
46. Goedert M (1998) Filamentous a-synuclein inclusions link multiple system atrophy with parkinson's disease and dementia with lewy bodies. Neuorosci Lett 251, 205-208.
47. Uversky VN, Gillespie JR, Fink AL (2000) Why are natively unfolded proteins unstructured under physiological conditions? Proteins 41, 415-427.
48. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97, 4897-4902.
49. Bisaglia M, Mammi S, Bubacco L (2009) Structural insights on physiological functions and pathological effects of a-synuclein. FASEBJ 23, 329-340.
50. Schulz JB (2008) Update on the pathogenesis of Parkinson's disease. J Neurol 255, 3-7.
51. Uversky VN (2007) Neurophatology, biochemistry, and biophysics of a-synuclein aggregation. J Neurochem 103, 1737.
52. Cherny, D, Hoyer W, Subramaniam V, Jovin TM (2004) Double-Stranded DNA Stimulates the fibrillation of a-synuclein in vitro and is associated with the Mature Fibrils:An Electron Microscopy Study. J Mol Biol 344, 929-938.
53. Hedge ML, Rao KS J (2007) DNA induces folding in a-synuclein: Understanding the mechanism using chaperone properties of osmolites. Arch Biochem Biophys 464, 57-69.
54. Gomez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hy-man BT (2000) a-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 99, 352-357.
55. McLean PJ, Kawamata H, Ribich S, Hyman BT (2000) Membrane association and protein conformation of a-synuclein in intact neurons. J Biol Chem 275, 8812-8816.
56. Leng Y, Chase TN, Bennet MC (2001) Muscarinic receptor stimulation induces translocation of an a-synucleinoligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 276, 28212-28218.
57. Sangchot P, Sharma S, Chetsawan B, Porter J, Govitrapong P, Ebadi M (2002) Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neuro sci 24, 143-153.
58. Goers J, Manning-Bog AB, McCormack AL, Millet IS, Do-niach S, Di Monte D, Uversky VN, Fink AL (2003) Nuclear localization of a-synuclein and its interaction with histones. Biochemistry 42, 8465-8471.
59. Zoghbi HY, Orr HT (2000) Glutamine repeats and neurode-generation. Annu Rev Neurosci 23, 217-247.
60. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30, 575-621.
61. Yamada M, Sato T, Tsuji S, Takahashi H (2008) CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 115, 71-86.
62. Friedman MJ, Wang CE, Li XJ, Li S (2008) Polyglutamine Expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J Biol Chem 283, 8283-8290.
63. Naito H, Oyanagi S (1982) Familial myoclonus epilepsy and choreathetosis: hereditary dentatorubral-pallidoluysian atrophy. Neurology 32, 798-807.
64. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M, Tomoda A, Miike T, Naito H, Ikuta F, Tsuji S (1994) Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 6, 9-13.
65. Nagafuchi S, Yanagisawa H, Ohsaki E, Shirayama T, Tadoko-ro K, Inone T, Yamada M (1994) Structure and expression of the gene responsible for the triplet repeat disorder, denta-torubral and pallidoluysian atrophy (DRPLA). Nat Genet 8, 177-182.
66. Zhang S, Xu L, Lee J, Xu T (2002) Drosophila atrophin ho-molog functions as a transcriptional corepressor in multiple developmental processes. Cell 108, 45-56.
67. Wang L, Tsai C-C (2008) Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl Recept Signal 6, e009.
68. Okamura-Oho Y, Miyashita T, Ohmi K, Yamada M (1999) Dentatorubral- pallidoluysian atrophy protein interacts through a proline-rich region near polyglutamine with the SH3 domain of an insulin receptor tyrosine kinase substrate. Hum Mol Genet 8, 947-957.
69. Yanagisawa H, Bundo M, Miyashita T, Okamura-Oho Y, Tadokoro K, Yamada M (2000) Protein binding of a DRPLA family through arginine-glutamic acid dipeptide repeats is enhanced by extended polyglutamine. Hum Mol Genet 9, 1433-1442.
70. Wood JD, Nucifora FC, Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacchi N, Lim JM, Ross CA (2000) Atrophin1, the dentatorubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription J Cell Biol 150, 939-948.
71. Ross CA, Poirier MA (2004) Protein aggregation and neu-rodegenerative disease. Nat Med 10, 10-17.
72. Nucifora FC Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL, Dawson TM, Ross CA (2003) Nuclear localization of a non-caspase truncation product of atrophin 1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 278, 1304713055.
73. Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar musclar atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671-680.
74. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 7779.
75. Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G (2007) Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropath Appl Neurol 33, 135-151.
76. Diamond MI, Robinson, MR, Yamamoto KR (2000) Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc Natl Acad Sci USA 97, 657-661.
77. Suzuki K, Kastuno M, Banno H, Sobue G (2009) Patho-genesis targeting therapeutics for spinal and bulbar muscular atrophy (SBMA). Neuropathology 29, 509-516
78. Vismara G, Simonini F, Onesto E, Bignamini M, Miceli V, Martini L, Poletti A (2009) Androgens inhibit androgen receptor promoter activation in motor neurons. Neurobiol Dis 33, 395-404.
79. Montie HL, Cho MS, Holder L, Lin Y, Tsvetkov AS, Finkbeiner S, Merry DE (2009) Cytoplasmic retention of polyglutamine-expanded andrgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18, 1937-1950.
80. Merry DE, Kobayashi Y, Bailey CK, Taye AA, Fischbeck KH, Cleavage, aggregation, and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum Mol Genet 7, 693-701.
81. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA (1997) Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chap-erone. Hum Mol Genet 8, 731-741.
82. Palazzolo I, Nedelsky NB, Askew CE, Harmison GG, Taylor JP, Fischbeck KH, Pennuto M (2010) B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J Neu-rosciRes 88, 2207-2216.
83. Banno H, Katsuno M, Suzuki K, Iguchi Y, Adachi H, Tana-ka F, Sobue G (2009) Molecular-targeted therapy for motor neuron disease. Brain Nerve 61, 891-900.
84. Echaniz-Laguna A, Bonsiges O, Loeffler JP, Bontillier AL (2008) Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem 15, 1263-1273.
85. Katuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, Doyu M, Sobue G (2006) Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 200, 8-18.
86. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13, 1183-1192
87. Karlson KM, Andresen JM, Orr HT (2009) Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev 19, 247-253.
88. Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, Orr HT (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrix associated structure. Nature 389, 971-974.
89. Uchihara T, Takeda Y, Kobayashi T, Kasuga T, Ishikawa K, Kirei K, Mizusawa H, Endo T, Hirokawa K, Kuroiwa T (2006) Unexpected clinicopathological phenotype linked to small elongation of CAG repeat in SCA1 gene. J Neurol 253, 396-398.
90. Duykaerts C, Diirr A, Cancel G, Brice A (1999) Nuclear inclusions in spinocerebellar ataxia type Acta Neuropathol 97, 201-207.
91. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948.
92. Clark HB, Burright EN, Yunis WS, Larson S, Wilcox C, Hartman B, Matilla A, Zoghbi HY, Orr HT (1997) Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate eVects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 17, 7385-7395.
93. Huynh DP, Figueroa K, Hoang N, Pulst SM (2000) Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 26, 44-50.
94. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S (2005) An integrative approach to gain insights into the cellular function of human ataxin-J Mol Biol 346, 203-214.
95. Pang JT, Giunti P, Chamberlain S, An SF, Vitaliani R Scar-avilli T, Martinian L, Wood NW, Scaravilli F, Ansorge O (2002) Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immonohistochemical study of two cases. Brain 125, 656-663
96. Al-Ramahi I, Perez AM, Lim, J, Zhang M, Sorensen R, De Haro M, Branco J, Pulst SM, Zoghbi HY, Botas J (2007) dAtaxin-2 mediates expanded Ataxin-1-induced Neurode-generation in a Drosophila Model of SCA PLoS Genetics 3,2551-2564.
97. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Onoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.Nat Genet 8, 221-228.
98. Sudarsky L, Coutinho P (1995) Machado-Joseph disease. Clin Neurosci 3, 17-22.
99. Takiyama Y, Oyanagi S, Kawashima S, Sakamoto H, Saito Km Yoshida M, Tsuji S, Mizuno Y, Nishizawa M (1994) A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology 44, 1302-1308.
100. Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, de Vos RA, Brunt ER, Klockgether T, Wullner U (2003) Gene expression profiling in ataxin-3-expressing cell lines reveals distinct effects of normal and mutant ataxin-J Neuropathol Exp Neurol 62, 1006-1018.
101. Evert BO, Araujo, J, Vieira-Saecker AM, de Vos RAI, Harendza S, Kolckgether T, Wiillner U (2006) Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci 26, 11474-11486.
102. Bichelmeier U, Schmidt T, Hubener J, Boy J, Ruttiger L, Habig K, Poths S, Bonin M, Knipper M, Schmidt WJ, Wilbertz J, Wolburg H, Laccone F, Riess O (2007) Nuclear localization of Ataxin-3 is required for the manifestation of symptoms in SCA3: In Vivo evidence. J Neurosci 27, 7418-7428.
103. Breuer P, Haacke A, Evert BO, Wullner U (2010) Nuclear aggregation of polyglutamine-expanded Ataxin-3 fragments scape the cytoplasmic quality control. J Biol Chem 285, 6532-6537.
104. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the Alpha 1A-voltage-dependent calcium channel. Nat Genet 15, 62-69
105. Ishikawa K, Tanaka H, Saito M, Ohkoshi N, Fujita T, Yoshizawa K, Ikeuchi T, Watanabe M, Hayashi A, Takiyama Y, Nishizawa M, Nakano I, Matsubayashi K, Miwa M, Shoji S, Kanazawa I, Tsuji S, Mizusawa H (1997) Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.Am J Hum Genet 61, 336-346.
106. Catterall WA (2000) Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16, 521-555.
107. Kordasiewicz HB, Gomez CM (2007) Molecular pathogen-esis of spinocerebellar ataxia type Neurotherapeutics 4, 285-294.
108. Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S, Tanabe T (2007) Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci 34, 261-270.
109. Watase K, Barrett CF, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, Unno T, Sun Y, Kasai S, Watanabe M, Gomez CM, Mizusawa H, Tsien RW, Zoghbi HY (2008) Spinocerebellar ataxya type 6 knockin mice develope a progressive neuronal dysfunction with age dependent accumulation of mutant Cav2.1 channels. Prc Natl Acad Sci USA 105, 11987-11992.
110. Seidel K, Brunt ER, de Vos RA, Dijk F, van der Want HJ, Rub U, den Dunnen WF (2009) The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia type (1998) Clin Neuropathol 28, 344-349.
111. Ishikawa K, Owada K, Ishida K, Fujigasaki H, Shun LM, Tsunemi T, Ohkoshi N, Toru S, Mizutani T, Hayashi M, Arai N, Hasegawa K, Kawanami T, Kato T, Makifuchi T, Shoji S, Tanabe T, Mizusawa H (2001) Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells. Neurology 56, 1753-1756.
112. Kubodera T, Takanori Y, Kiyoshi O, Kinya I, Miura H, Matsuoka T, Mizusawa H (2003) Proteolytic cleavage and cellular toxicity of the human alpha 1A calcium channel in spinocerebellar ataxia type Neurosci Lett 341, 74-78
113. Ishiguro T, Ishikawa K, Takahashi M, Obayashi M, Amino T, Sato N, Sakamoto M, Fujigasaki H, Tsuruta F, Dolmetsch R, Arai T, Sasaki H, Nagashima K, Kato T, Yamada M, Taka-hashi H, Hashizume Y, Mizusawa H (2010) The carboxy-terminal fragment of a1A calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. Acta Neuropathol 119, 447-464
114. Enevoldson TP, Sanders MD, Harding AE (1994) Autosomal dominant cerebellar ataxia with pigmentary macular distro-phy. A clinical and genetic study of eight families. Brain 117, 445-460.
115. Gouw LG, Digre KB, Harris CP, Haines JH, Ptacek LJ (1994) Autosomal dominant cerebellar ataxia with retinal degeneration: clinical, neuropathologic, and genetic analysis of a large kindred. Neurology 44, 1441-1447.
116. David G, Durr A, Stevanin G, Cancel G, Abbas N, Yvert G, Benomar A, Belal S, Lebre AS, Abada-Bendib M, Grid D, Holmberg M, Yahyaoui M, Hentati F, Chkill T, Agid Y, Brice A (1998) Molecular and clinical correlations in auto-somal dominant cerebellar ataxia with progressive macular distrophy. Hum Mol Genet 7, 165-170.
117. Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, Miguet L, Potier N, Van-Dorsselaer, Wurtz JM, Mandel JL, Tora L, Devys D (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13, 1257-1265.
118. Palhan VB, Chen S, Peng GH, Tjernberg A, Gamper AM, Fan Y, Chait BT, La Spada AR, Roeder RG (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci U S A 102, 8472-8477.
119. Garden GA, La Spada AR (2008) Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neu-rodegeneration. Cerebellum 7, 138-149.
120. Bowman AB, Yoo S-Y, Dantuma NP, Zoghbi Y (2005) Neuronal dysfunction in a polygluta mine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 14, 679-691.
121. Mookerjee S, Papanikolau T, Guyenet SJ, Sampath V, Lin A, Vitelli C, DeGiacomo F, Sopher BL Chen SF, LaSpada AR, Ellerby LM (2009) Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. J Neurosci 29, 15134-15144.
122. Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, Yamada M, Takahashi H, Tsuji S (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA binding protein gene: a new polyglu-tamine disease? Hum Mol Genet 8, 2047-2053.
123. Rolfs A, Koeppen AH, Bauer I, Buhlmann S, Topka H, Schols L, Riess O (2003) Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 54, 367-375.
124. Gill G, Tjian R (1992) Eukaryotic coactivators associated with the TATA box binding protein. Curr Opin Genet Dev 2, 236-242.
125. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 10, 1441-1448.
126. Bruni AC, Takahashi-Fugigasaki J, Maltecca F, Foncin JF, Servadio A, Casari G, D'Adamo P, Maletta R, Curcio SA, DeMichele G, Filla A, El Hachimi K, Duykaerts C (2004) Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol 61, 1314-1320.
127. Friedman MJ, Wang CE, Li XJ, Li S (2008) Polyglutamine expansion reduces the association of TATA binding protein with DNA and induces DNA-binding-independent neurotox-icity. J Biol Chem 283, 8283-8290.
128. Sha AG, Friedman MJ, Huang S, Roberts M, Li XJ, Li S (2009) Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type Hum Mol Genet 18, 4141-4152.
129. The Huntington's Disease Collaboration Research Group (1993) A novel gene containing a trinucleotide repeats that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
130. Bates, G(2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644.
131. Kazantsev, AG, Hersch, SM (2007) Drug targeting of dysreg-ulated transcription in Huntington's disease. Prog Neurobiol 83, 249-259.
132. Browne, SE (2008) Mitochondria and Huntington's disease pathogenesis. Ann NY Acad Sci 1147, 358-382.
133. Ortega Z, Diaz-Hernandez M, Lucas JJ (2007) Is the ubiquitin-proteasome system impaired in Huntington's disease? Cell Mol Life Sci 64, 2245-2257.
134. Bossy-Wetzel E, Petrilli A, Knott AB (2008) Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 31, 609-616.
135. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qin Z, Chen JD, Nevins JR, Aronin N, Figlia M (2002) Huntingt in is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription J Biol Chem 277, 7466-7476.
136. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington's disease. Trends Genet 19, 233-238.
137. Li XJ, Li SH (2005) HAP1 and intracellular trafficking. Trends Pharmacol Sci 26, 1-3.
138. Augood SJ, Faull RL, Emson PC (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42, 215-221.
139. Augood SJ, Faull RL, Love DR, Emson PC (1996) Reduction in encephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72, 1023-1036.
140. Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney Jr JB, Davies SW, Bates GP, Young AB (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc LondB Biol Sci 354, 981-989.
141. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9, 1259-1271.
142. Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM (2002) Polyglutamine and transcription: gene expression changes shared byDRPLA and Hunt-ington's disease mouse models reveal contextin dependent effects. Hum Mol Genet 11, 1927-1937.
143. Dorsman JC, Smoor MA, Maat-Schieman ML, Bout M, Sies-ling S, van Duinen SG, Verschuuren JJ, den Dunnen JT, Roos RA, van Ommen GJ (1999) Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mamalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain. Philos Trans R Soc Lond B Biol Sci 354, 1061-1067.
144. Martindale D, Hackman A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18, 150-154.
145. Ravikumar B, Duden R, Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11, 1107-1117.
146. Rubinsztein DC, Huntington JA (2006) Paradoxical aggregation versus oligomerisation properties of mutant and wild-type huntingtin fragments. Exp Neurol 199, 243-244.
147. Masino L, Pastore A (2002) Glutamine repeats: structural hypotheses and neurodegeneration. Biochem Soc T 30, 548551.
148. Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Ross SA, Bjorkman PJ (2002) A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A 99, 11634-11639.
149. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRoc-co DP, Yohrling GJ, Clark TW, Bouzou B, Cha JJ (2008) Huntingtin modulates transcription, occupies gene promoters In Vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 28, 10720-10733.
150. Rowland LP, Shneider MD (2001) Amyotrophic lateral sclerosis. New Engl J Med 344, 1688-1700.
151. Turner B, Talbot K (2008) Transgenic, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. ProgNeurobiol 85, 94-134.
152. Rakhit R, Chakrabartty A (2006) Structure, folding, and mis-folding of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim Biophys Acta 1762, 1025-1037.
153. Wijesekera LC, Leigh PN (2009) Amyotrophic lateral sclerosis. Orphanet JRare Dis 4:3.
154. Raha S, Robinson BH (2000) Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 25, 502508.
155. Fridovich I (1975) Superoxides dismutases. Annu Rev Biochem 44, 147-159.
156. Jiang W, Han Y, Zhou R, Zhang L, Liu C (2007) DNA is a template for accelerating the aggregation of copper, zinc superoxide dismutase. Biochemistry 46, 5911-5923.
157. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rah-mani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Hertzfeldt B, Van der Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
158. Shaw BF, Valentine JS (2007) How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein. Trends Biochem Sci 32, 78-85.
159. Chang L-Y, Slot JW, Genze HJ, Crapo JD (1988) Molecular Immunocytochemistryof the ZnCu Superoxide Dismutase in Rat Hepatocytes. J Cell Biol 107, 2169-2179.
160. Del Maestro R, Mc Donald W (1989) Subcellular localization of superoxides dismutases, glutathione peroxidase and catalase in developing rat cerebral
161. Ookawara T, Kizaki T, Takayama E, Imazeki N, Matsubara O, Ikeda Y, Suzuki K, Ji LL, Tadakuma T, Taniguchi N, Ohno H (2002) Nuclear translocation of extracellular superoxide dismutase. Biochem Biophys Res Commun 296, 54-61
162. Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL, Cleveland DW, Gitlin JD, Wong PC (2002) Mutant SOD1 causes motor neuron disease independent of copper-chaperone-mediated copper loading. Nat Neurosci 5, 301-307.
163. Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, Brown Jr RH, Hayward LJ (2002) Familial amyotrophic lateral sclerosis associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem 277, 15932-15937.
164. Lindberg MJ, Tibell L, Oliveberg M (2002) Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci USA 99, 16607-16612.
165. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS (1997) Decreased Zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 69, 1936-1944.
166. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, Cashman NR, Kondejewsky LH, Chakrabartty A (2002) Oxidation induced misfolding and aggregation of su-peroxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 277, 47551-47556.
167. Stathopulos PB, Rumfeldt JA, Scholz GA, Irani RA, Frey HE, Hallewell RA, Lepock JR, Meiering EM (2003) Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci USA 100, 7021-7026.
168. Khare SD, Caplow M, Dokholyan NV (2004) The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 101, 15094-15099.
169. Abernethy JL, Steinman HM, Hill RL (1974) Bovine erythrocyte superoxide dismutase. Subunit structure and sequence location of the intrasubunit disulfide bond. J Biol Chem 249, 7339-7347.
170. Banci L, Bertini I, Durazo A, Girotto S, Gralla EB, Martinelli M, Valentine JS, Vieru M, Whitelegge JP (2007) Metal-free SOD1 forms amyloid-like oligomers: A possible general mechanism for familial ALS. Proc Natl Acad Sci U SA 104, 11263-11267.
171. Banci L, Bertini I, Boca M, Calderone V, Cantini F, Girotto S, Vieru M (2009) Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. Proc Natl Acad Sci USA 106, 6980-6985.
172. Tiwari A, Hayward LJ (2003) Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J Biol Chem 278, 5984-5992.
173. Arnesano F, Banci L, Bertini I, Martinelli M, Furukawa Y, O'Halloran TV (2004) The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J Biol Chem 279, 47998-48003.
174. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabarty A (2004) Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 279, 15499-15504.
175. Jiang W, Zhang B, Yin J, Liu L, Wang L, Liu C (2008) Polymorphism of the SOD1-DNA aggregation species can be modulated by DNA. Biopolimers 89, 1154-1169
176. Neumann N, Samphatu DM, Kwong LK, Truax AC, Mic-senyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Biller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzshmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
177. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin positive tau negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602-611.
178. Shan X, Vocadlo D, Krieger C (2009) Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. Neurosci Lett 458, 70-74.
179. Zhang Y-J, Xu Y-F, Cook C, Gendron TF, Roettges P, Link CD, Lin W-L, Tong J, Castanedes-Casey M, Ash P, Gass J, Rangachari V, Buratti E, Baralle F, Golde TE, Dickson DW, Petrucelli L (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 106, 7607-7612.
180. Caughey B, Kocisko DA (2003) A nucleic-acid accomplice? Nature 425, 673-674
181. Zou WQ, Gambetti P (2007) Prion: the chameleon protein. Cell Mol Life Sci 64, 3266-3270.
182. Aguzzi A, Sigurdson C, Heikenwaelder M (2008) Molecular mechanisms of prion pathogenesis. Annu Rev Pathol Mech Dis 3, 11-40.
183. LeBrun M, Huang H, Li X (2008) Susceptibility of cell substrates to PrPSc infection and safety control measures related to biological and biotherapeutical products. Prion 2, 17-22.
184. Birkmann E, Riesner D (2008) Prion Infection. Seeded fibrillization or more? Prion 2, 67-72.
185. Sigurdson CJ (2008) A prion disease of cervids: Chronic wasting disease. Vet Res 39, 41.
186. Moore RA, Taubner LM, Priola SA (2009) Prion protein misfolding and disease. Curr Opin Struc Biol 19, 14-22.
187. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144.
188. Baskakov IV, Legname G, Gryczynsky Z, Prusiner SB (2004) The peculiar nature of unfolding of the human prion protein. Protein Sci 13, 586-595.
189. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95, 13363-13383.
190. Linden R, Martins VR, Prado MA, Cammarota M, Izquier-do I, Brentani RR (2008) Physiology of the prion protein. PhysiolRev 88, 673-728.
191. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB (1993) Conversion of a-helices into (-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90, 10962-10966.
192. Riek R, Hornemann S, Wider G, Glockshuber R, Wuthrich K (1997) NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Let 413, 282-288.
193. Horwich AL, Weissman JS (1997) Deadly conformations-protein misfolding in prion disease. Cell 89, 499-510.
194. Donne DG, Viles JH, Groth D, Mehlhorn I, James, TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ (1997) Structure of the recombinant full-length hamster prion protein PrP (29231): The N terminus is highly flexible. Proc Natl Acad Sci USA 94, 13452-13457.
195. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B (1994) Cell-free formation of protease-resistant prion protein. Nature 370, 471-474.
196. Nandi PK, Leclerc E (1999) Polymerization of murine re-combinant prion protein in nucleic acid solution. Arch Virol 144, 1751-1763.
197. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D, Silva JL (2001) DNA converts cellular prion protein into the (-sheet conformation and inhibiots prion peptide aggregation. J Biol Chem 276, 49400-49409.
198. Fornai F, Ferrucci M, Gesi M, Bandettini di Poggio A, Giorgi FS, Biagioni F, Paparelli A (2006) A hypothesis on prion disorders: are infectious, inherited, and sporadic causes so distinct? Brain Res Bull 69, 95-100
199. Glatzel M, Stoeck K, Seeger H, Luhrs T, Aguzzi A (2005) Human prion diseases: molecular and clinical aspects. Arch Neurol 62, 545-552.
200. Grossman A, Zeiler B, Sapirstein V (2003) Prion protein interactions with nucleic acid: possible models for prion disease and prion function. Neurochem Res 28, 955-963.
201. Nandi P (1998) Polymerization of human prion protein pep-tide HuPrP 106-126 to amyloid in nucleic acid solution. Arch Virol 143, 1251-1263.
202. Weiss S, Proske D, Neumann M, Groschup M, Kretzschmar H, Famulok M, Winnacker E (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71, 87908797.
203. Silva JL, Mauricio L, Lima TR, Foguel D, Cordeiro Y (2008) Intringuing nucleic-acid-binding features of mammaliam pri-on protein. Trends Biochem Sci 33, 132-140.
204. Mange A, Crozet C, Lehmann S, Beranger F (2004) Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. J cell Sci 117, 2411-2416.
205. Pfeifer K, Bachmann M, Schroder HC, Forrest J, Muller WE (1993) Kinetics of expression of prion protein in uninfected and scrapie-infected N2a mouse neuroblastoma cells. Cell Biochem Funct 11, 1-11.
206. Lorenz H, Windl O, Kretzschmar HA (2002) Cellular phe-notyping of secretory and nuclear prion proteins associated with inherited prion diseases. J Biol Chem 277, 8508-8516.
207. Zanusso G, Petersen RB, Jin T, Ying Y, Kanoush R, Ferrari S, Gambetti P, Singh N (1999) Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 274, 23396-23404.
208. Gabus C, Derrington E, Leblanc P, Chainerman J, Dormont D, Swietnicki W, Morillas M, Surewicz W, Marc D, Nandi P, Darlix JL (2001) The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1 ribonucleic acid. J Biol Chem 276, 1930119309.
209. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid (-protein (A() assembly: A(40 and A(42 oligomerize through distinctpathways. Proc Natl Acad Sci USA 100, 330-335.
210. Rauk A (2008) Why is the amyloid beta peptide of Alzheimer's disease neurotoxic? Dalton Trans, 1273-1282.
211. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B (1994) Cell-free formation of protease-resistant prion protein. Nature 370, 471-474.
212. Padmaraju V, Indi SS, Rao KSJ (2010) New evidences on Tau-DNA interactions and relevance to neurodegeneration. Neurochem Int 57, 51-57.
213. OrtegaZ, Diaz-Hernandez M, Maynard C, Hernandez F, Dantuma NP, Lucas JJ(2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/Proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 30, 3675-3688.
214. Xu S, Zhou M, Yu S, Cai Y, Zhang A, Ueda K, Chan P (2006) Oxidative stress induces nuclear translocation of C-terminus of a-synuclein in dopaminergic cells. Biochem Biophys Res Commun 342, 330-335.
215. Altar CA, Vawter MP, Ginsberg SD (2009) Target Identification for CNS Diseases by Transcriptional Profiling. Neu-ropsychopharmacology 34, 18-54.
216. Tsevelekey V, Rubio R, Vamvakas S-S, White J, Taoufik E, Petit E, Quackenbush J, Probert L (2010) Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changes. Genomics 96, 82-91.
217. Tan MG, Chua W-T, Esiri MM, Smith AD, Vinters HV, Lai MK (2010) Genome wide profiling ao altered gene expression in the neocortex of Alzheimer's disease. J Neurosci Res 88, 1157-1169.
218. Huang J, Chen YJ, Bian WH, Yu J, Zhao YW, Liu XY (2010) Unilateral amyloid-(25-35 injection into the rat amygdala increases the expressions of aberrant tau phosphorylation kinases. Chin Med J123, 1211-1314.
219. Brossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, Verhaagen J (2009) Analysis of gene expression in Parkinson's disease: possible involvement of neu-rotrophic support and axon guidance in dopaminergic cell death. Brain Pathol 19, 91-107.
220. Youdin MB (2003) What have we learnt from cDNA mi-croarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease. J Neural Transm Suppl 65, 73-88.
221. DArrigo A, Colavito D, Pena-Altamira E, Fabris M, Dam M, Contestabile A, Leon A (2010) Transcriptional profiling in thr lumbar spinal cord of a mouse model of amyotrophic lateral sclerosis: a role for wild-type superoxide dismutase 1 in sporadic disease. J Mol Neurosci 41, 404-415.
222. Wang XS, Simmons Z, Liu W, Boyer PJ, Conor JR (2006) Differential expression of genes in amyotrophic lateral sclerosis by profiling the postmortem cortex. Amyotroph Lateral Scler 7, 201-210.
223. Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Hunt-ington's disease mouse models reveal context-independent effects. Hum Mol Genet 11, 1927-1937.
224. Hoshino M, Qi M, Yoshimura N, Miyashita T, Tagawa K, Wada Y, Enokido Y, Marubuchi S, Harjes P, Arai N, Oyanagi K, Blandino G, Sudol M, Rich T, Kanazawa I, Wanker EE, Saitoe M, Okazawa H (2006) Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and pJ Cell Biol 172, 589-604.
225. Sorensen G, Medina S, Parchaliuk D, Phillipson C, Rober-ston C, Booth SA (2008) Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics 9, 114
226. Moody LR, Herbst AJ, Yoo HS, Vanderloo JP, Alken JM (2009) Comparative prion disease gene expression profiling using the prion disease mimetic, cuprizone. Prion 3, 99-109.